ALFA Finder| Revenue growth | 18% YoY growth; highest ever quarterly revenue. |
|---|---|
| Margins | EBITDA margin improved through operational leverage and business mix. |
| Demand visibility | Positive outlook for CDMO and Exports; TGx expected to bridge gaps. |
| Management confidence | High; citing 14 consecutive quarters of record revenue. |
Growth
Q1FY27 Revenue grew 18% YoY to INR 248 Cr. EBITDA (excl. ESOP) grew 26% to INR 34 Cr; PAT grew 37% to INR 25 Cr.
Outlook
Plant 6 commercialization on track for H1FY27. Target revenue capacity of INR 1,100 Cr once fully operational.
Risks
Trade Generics vertical impacted by discontinuation of codeine-based products. API price volatility remains a monitoring point.
Last quarter's promises, checked
Delivered
- Plant 6 mechanical completion → achieved (H1FY27 launch on track) (= BEAT)
- Revenue growth of 19% YoY for FY26 → delivered 19% (= BEAT)
- Maintain ROCE/ROE above 25% → sustained above 25% (= BEAT)
Partly delivered
- Fill codeine-based revenue loss with alternates → partially filled in Q4 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹998.35
- Market cap
- ₹2,095 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 31.4×Sector 43.8×
- Promoter holding
- 63.31%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Management Change
Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.
Windlas Biotech Results Update
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
Windlas Biotech Investor Presentation: Key Takeaways
H1FY27 revenue Rs 512 Cr (+18%), adj. PAT Rs 50 Cr (+33%, 9.7% margin); reported PAT flat at Rs 36 Cr on ESOP charges. CDMO-led growth; Plant-6 commercialised.
Windlas Biotech Q2 FY27 Results: Net Profit ₹18.1 Cr, Up 1.7% YoY
Windlas Biotech Ltd reported revenue from operations of ₹263.9 Cr (+18.7% YoY) and net profit of ₹18.1 Cr (+1.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.1 Cr · +1.7% YoY
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Windlas Biotech Board Meeting Date
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.